The first-in-class molecule shuts down oestrogen-sensitive breast cancer in a new way, researchers said.
First-in-class drugs are those that work by a unique mechanism - in this case, a molecule that targets a protein on the oestrogen receptor of tumour cells.
The potential drug offers hope for patients whose breast cancer has become resistant to traditional therapies.
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morning
YOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more